Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.52 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.51 |
| ▸ | HTR3B | O95264 | 1/20 | 0.51 |
| ▸ | HTR3A | P46098 | 1/20 | 0.51 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.51 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylamine SCHEMBL15743165 | 0.97 | SLC7A5 (0.56) | SLC7A5CTBP2HDAC3HDAC4HDAC1 | |
| SCHEMBL12400239 | 0.87 | SLC7A5 (0.68) | SLC7A5ALDH1A1GAAGFERHSP90AB1 | |
| SCHEMBL27726131 | 0.85 | L3MBTL1 (0.46) | SLC7A5CTBP2HDAC3HDAC4HDAC1 | |
| SCHEMBL31244291 | 0.84 | CTBP2 (0.56) | CTBP2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL9545043 | 0.83 | KMT2A (0.54) | KMT2AALDH1A1MEN1HPGDSMN1; SMN2 | |
| SCHEMBL7640165 | 0.83 | CTBP2 (0.51) | CTBP2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL406058 | 0.83 | MAOB (0.58) | CTBP2HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL19068063 | 0.82 | TAAR1 (0.54) | MAOBCYP4F2CYP4A11 | |
| SCHEMBL480042 | 0.82 | SLC7A5 (0.59) | SLC7A5ALDH1A1GAAGFERHSP90AB1 | |
| SCHEMBL6970344 | 0.82 | CTBP2 (0.54) | CTBP2HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150322094-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2015-11-12 | — | — | US | claimed |
| EP-4724435-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2025233641-A1 | NOVEL PHOTOINDUCIBLE KINASE INHIBITORS FOR TREATING PROLIFERATIVE AND VASOPROLIFERATIVE DISEASES | SEMMELWEIS EGYETEM (HU) | 2025-11-13 | — | — | WO | disclosed |
| US-12435181-B2 | Formulations capable of reacting with or removal of molecular oxygen | LI SHENSHEN (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2024254532-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-12059422-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | MEI PHARMA, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| CN-117736104-A | Method for synthesizing butanedicarboxylate derivative by visible light catalysis | 常州大学 | 2024-03-22 | — | — | CN | disclosed |
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20010047105-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER PRODUCTS INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001046140-A1 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-1110949-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | Pfizer Products Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2001000206-A1 | VLA-4 INHIBITOR COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-01-04 | — | — | WO | disclosed |
| US-6124343-A | Substituted phenyl compounds with a substituent having a thienyl ring | RHONE-POULENC RORER LIMITED (GB) | 2000-09-26 | — | — | US | disclosed |
| EP-0805802-B1 | SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS | RHONE POULENC RORER LTD (GB) | 2000-08-16 | — | — | EP | disclosed |
| US-6048893-A | Substituted phenyl compounds with a substituent having A 1,3-benzodioxole ring | RHONE-POULENC RORER LIMITED (GB) | 2000-04-11 | — | — | US | disclosed |
| CN-1178525-A | Substituted phenyl compounds as endothelin antagonists | RHONE POULEUC RORER LTD (GB) | 1998-04-08 | — | — | CN | disclosed |
| EP-0805802-A1 | SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS | RHONE-POULENC RORER LIMITED (GB) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022978-A1 | SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS | RHONE POULENC RORER LIMITED (GB) | 1996-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | VIM, ACE, ACE2 | SLC7A5 1967/4885CTBP2 2750/4885HDAC3 3174/4885 |
| US-20150322094-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | CAT, HSF1, HPD | SLC7A5 688/4885CTBP2 3694/4885HDAC3 1379/4885 |
| US-12059422-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | CCNI, CCNK, CCNA1 | SLC7A5 2749/4885CTBP2 4605/4885HDAC3 1521/4885 |
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | SMARCA2, SMARCE1, SMARCB1 | SLC7A5 4425/4885CTBP2 443/4885HDAC3 1348/4885 |
| US-20010047105-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | SLC7A5 4022/4885CTBP2 4098/4885HDAC3 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.